In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2452-2455

  García Garrote, Fernando ^a   Cercenado, Emilia ^a   Alcalá, Luis ^a   Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; ERYTHROMYCIN; GLYCOPEPTIDE; ORITAVANCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 2542508472     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2452     Document Type: Article

References (12)

1. Banerjee, S. N., T. G. Emori, D. H. Culver, R. Gayne, W. R. Jarvi, T. Horan, J. R. Edward, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial bloodstream infections in the United States, 1980-1989. National Nosocomial Infection Surveillance System. Am. J. Med. 91(Suppl. 3B):86S-89S.
2. Biavasco, F., C. Vignaroli, R. Lupidi, E. Manso, B. Facinelli, and P. E. Varaldo. 1997. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41:2165-2172.
3. Centers for Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42:597-599.
4. Fasola, E., S. K. Spangler, L. M. Ednie, M. R. Jacobs, S. Bajaksouzian, and P. C. Appelbaum. 1996. Comparative activities of LY333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:2661-2663.
5. Hackbarth, C. J., and H. F. Chambers. 1989. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob. Agents Chemother. 33:995-999.
6. Jones, R. N., M. S. Barrett, and M. E. Erwin. 1996. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. 41:488-493.
7. Mercier, R. C., H. H. Houlihan, and M. J. Rybak. 1997. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41:1307-1312.
8. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing: sixth informational supplement. M100-S6. National Committee for Clinical Laboratory Standards, Wavne, Pa.
9. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Synder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
10. Schwalbe, R. S., A. C. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419.
11. Wilkie, S. C., N. J. Snyder, M. J. Zweifel, D. R. Stack, D. L. Mullen, T. F. Butler, T. I. Nicas, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1995. New semisynthetic glycopeptide antibiotics: structure-activity relationship of the N-alkylated disaccharide, abstr. F244, p. 156. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Zelenitsky, S. A., J. A. Karlowsky, G. G. Zhanel, D. J. Hoban, and T. Nicas. 1997. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrob. Agents Chemother. 41:1407-1408.